AI Article Synopsis
- The goal in cancer radiotherapy is to deliver radiation precisely to tumors while minimizing damage to healthy tissue.
- Injectable systemic radionuclide therapies show potential in achieving this, even for small metastases and single cancer cells.
- This review focuses on the different methods for determining the location of radiopharmaceuticals in cells and their pros and cons, especially in relation to dosimetry challenges for certain radionuclides.
Article Abstract
In oncology, the holy grail of radiotherapy is specific radiation dose deposition in tumours with minimal healthy tissue toxicity. If used appropriately, injectable, systemic radionuclide therapies could meet these criteria, even for treatment of micrometastases and single circulating tumour cells. The clinical use of α and β particle-emitting molecular radionuclide therapies is rising, however clinical translation of Auger electron-emitting radionuclides is hampered by uncertainty around their exact subcellular localisation, which in turn affects the accuracy of dosimetry. This review aims to discuss and compare the advantages and disadvantages of various subcellular localisation methods available to localise radiopharmaceuticals and radionuclides for in vitro investigations.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7610823 | PMC |
| http://dx.doi.org/10.1016/j.nucmedbio.2021.03.010 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Synthesis and characterisation of DOTA-kisspeptin-10 as a potential gallium-68/lutetium-177 pan-tumour radiopharmaceutical.
J Neuroendocrinol
January 2025
Centre for Neuroendocrinology, University of Pretoria, Pretoria, South Africa.
Kisspeptin (KISS1) and its cognate receptor (KISS1R) are implicated in the progression of various cancers. A gallium-68 labelled kisspeptin-10 (KP10), the minimal biologically active structure, has potential as a pan-tumour radiopharmaceutical for the detection of cancers. Furthermore, a lutetium-177 labelled KP10 could find therapeutic application in treating oncological diseases.
View Article and Find Full Text PDFSentinel lymph nodes biopsy for malignant tumors using Technefit radioactive colloid Technetium Tc.
Folia Med (Plovdiv)
December 2024
Botkin Hospital, Moscow, Russia.
Technetium-99m (99mTc) is a short-lived nanocolloid nuclide widely used by oncologists to diagnose and identify cancer dissemination.
View Article and Find Full Text PDFRetrospective study of post-treatment I SPECT/CT imaging for personalizing therapy of patients with differentiated thyroid cancer.
Folia Med (Plovdiv)
December 2024
Military Medical Academy, Sofia, Bulgaria.
The absence of anatomical landmarks in the whole body scan makes it challenging to precisely localize 131I uptake, which is used to treat patients with differentiated thyroid cancer (DTC). Recently, SPECT/CT studies have been utilized to increase the diagnostic sensitivity and specificity.
View Article and Find Full Text PDF"Motion Capture Suit Sign" for Immunotherapy-Induced Inflammatory Arthritis on 99mTc-MDP Bone Scintigraphy.
Clin Nucl Med
February 2025
Division of Chest and Critical Care, Department of Internal Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan.
We report the 99mTc-MDP bone scan of a 44-year-old man with a history of lung adenocarcinoma and recent multiple joint pain after completing pembrolizumab immunotherapy treatment. This interesting image of symmetric uptakes around bilateral joints throughout the skeleton resembles the ball sensors on a motion capture suit. Hence, we recommend naming this distinctive imaging appearance as the "motion capture suit" sign.
View Article and Find Full Text PDFPurpose: The aim of this study was to evaluate the efficacy and safety of 177Lu-DOTA-IBA for pain palliation in participants with bone metastases and confirm its potential for treating bone metastasis.
Patients And Methods: Overall, 69 participants with bone metastases were included. 68Ga-DOTA-IBA PET/CT was performed within 1 week before treatment.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!